Long-term Outcome after hyper-CVAD and Imatinib for De Novo or Minimally Treated Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph-ALL)

Slides:



Advertisements
Similar presentations
台北榮總血液腫瘤科 楊元豪 / 高志平大夫. 2 Background Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only potentially curative treatment in patients.
Advertisements

IN ACUTE MYELOID LEUKEMIA, THE USE IN INDUCTION OF STANDARD DOSE ARA-C IS ASSOCIATED WITH A BETTER QUALITY OF RESPONSE AS COMPARED TO AN INDUCTION REGIMEN.
The National CML Society 2012 CML UPDATE “What’s New? What’s Coming?” Luke Akard MD Co-Director Indiana Blood and Marrow Transplantation Program.
Chronic Myeloid Leukemia: Treatment Success and Milestones
Long Term Follow-Up After Imatinib Cessation for Patients in Deep Molecular Response: The Update Results of the STIM1 Study1 Preliminary Report of the.
Safe and Effective Re-Induction of Complete Remissions in Adults with Relapsed B-ALL Using 19-28z CAR CD19-Targeted T Cell Therapy Davila ML et al. Proc.
Results of a Phase 2 Randomised, Open- Label, Study of Lower Doses of Quizartinib (AC220; ASP2689) in Subjects with FLT3-ITD Positive Relapsed or Refractory.
The role of transplant for CML in the imatinib era Dr Wendy Ingram Consultant Haematologist University Hospital of Wales.
Monitoring CML Treatment: Addressing the Issues for the Community Hematologist/Oncologist Hagop M. Kantarjian, MD Chairman; Professor, Department of Leukemia.
Treatment of CML Transplant or Imatinib? Mark B Juckett MD Section of Hematology/BMT University of Wisconsin.
Treatment of Non- Hodgkin’s Lymphoma. Precursor B cell Lymphoblastic Leukemia Remission induction with combination therapy Consolidation phase: –High.
MANAGEMENT OF MANTLE CELL LYMPHOMA IN TUNISIA R BEN LAKHAL, L KAMMOUN, K ZAHRA, S KEFI Sousse 25 MAY 2012.
Dose Interruption/Reduction of Tyrosine Kinase Inhibitors in the First 3 Months of Treatment of CML Is Associated with Inferior Early Molecular Responses.
LIBYAN EXPERIENCE IN PEDIATRIC ACUTE MYELOID LEUKEMIA Fathia El Riani, Rasem Al Ajnef, Elham Sbita, Salem Zarroug Departement of pediatric hematology-oncology.
5-Azacitidine For Myelodysplasia Before Allogeneic Hematopoietic Cell Transplantation Field T et al. Bone Marrow Transplant 2009:[Epub ahead of print].
Alternating Courses of CHOP and DHAP Plus Rituximab (R) Followed by a High-Dose Cytarabine Regimen and ASCT is Superior to Six Courses of CHOP Plus R Followed.
Reduced-Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (allo-SCT) for Relapsed/Refractory Hodgkin Lymphoma (HL) in the Brentuximab.
ANCO ASH 2005 Review Acute Leukemias Feb 22, 2006 Charles Linker MD.
ENESTnd 24-Month Update: Continued Superiority of Nilotinib versus Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.
A Phase II Study of Lenalidomide as Initial Treatment of Elderly Patients with Chronic Lymphocytic Leukemia Xavier Badoux, William Wierda, Susan O'Brien,
Improved Survival in Patients with First Relapsed or Refractory Acute Myeloid Leukemia (AML) Treated with Vosaroxin plus Cytarabine versus Placebo plus.
Rituximab Maintenance versus Wait and Watch After Four Courses of R-DHAP Followed by Autologous Stem Cell Transplantation in Previously Untreated Young.
Early Molecular and Cytogenic Response Is Predictive for Long-Term Progression-Free and Overall Survival in Chronic Myeloid Leukemia (CML) Hanfstein B.
Treatment of CML. Goal of Therapy Complete molecular remission and cure – Achieve prolonged, durable, nonneoplastic, nonclonal hematopoiesis, – Eradication.
Dr Nauman Butt – Royal Liverpool University Hospital CML Patient Seminar - 14 th November 2015 What is CML? How do we treat it? Get up to speed…
Inotuzumab Ozogamicin (IO; CMC544), a CD22 Monoclonal Antibody Attached to Calicheamycin, Produces Complete Response (CR) plus Complete Marrow Response.
Switching to Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase with Suboptimal Cytogenetic Response on Imatinib: Results from the LASOR.
A Phase II Study of Lenalidomide for Previously Untreated Deletion (del) 5q Acute Myeloid Leukemia (AML) Patients Age 60 or Older Who Are Not Candidates.
Future directions: Can we improve outcomes in relapsed/refractory DLBCL or aggressive NHL? Bertrand Coiffier Service d’Hématologie Hospices Civils de Lyon.
Low Dose Decitabine Versus Best Supportive Care in Elderly Patients with Intermediate or High Risk MDS Not Eligible for Intensive Chemotherapy: Final Results.
TREATMENT. Phases of treatment Induction chemotherapy Postremission therapy *Initial goal: quickly induce CR *Therapy depends on patient age.
Phase II Trial of R-CHOP plus Bortezomib Induction Therapy Followed by Bortezomib Maintenance for Previously Untreated Mantle Cell Lymphoma: SWOG 0601.
Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia.
Treatment. Phases of treatment Induction chemotherapy Postremission therapy *Initial goal: quickly induce CR *Therapy depends on patient age.
Case report Sudden blastic transformation in patient with chronic myeloid leukemia treated with imatinib mesylate Mehrdad Payandeh,MD Hematology, Medical.
Case 297 Guilin Tang and Sa A. Wang Department of Hematopathology UT MD Anderson Cancer Center.
Future of CML treatments – Are they getting us closer to cure? Andreas Hochhaus Universitätsklinikum Jena, Germany.
Daunorubicin VS Mitoxantrone VS Idarubicin As Induction and Consolidation Chemotherapy for Adults with Acute Myeloid Leukemia : The EORTC and GIMEMA Groups.
J Clin Oncol August Vol 28 R2. 석화영 / Pf. 윤휘중.
Kantarjian HM et al. Proc ASH 2012;Abstract Long-Term Follow-Up of Ongoing Patients in 2 Studies of Omacetaxine Mepesuccinate for Chronic Myeloid.
The Challenge of Monitoring CML When Resources Are Limited Jorge Cortes, MD Chief, CML & AML Section Department of Leukemia MD Anderson Cancer Center.
39th ESMO Congress Madrid, Spain – 30 September Poster 979P
New Findings in Hematology: Independent Conference Coverage
1 Stone RM et al. Proc ASH 2015;Abstract 6.
Palumbo A et al. Proc ASH 2012;Abstract 200.
Maury S et al. Proc ASH 2015;Abstract 1.
IFM/DFCI 2009 Trial: Autologous Stem Cell Transplantation (ASCT) for Multiple Myeloma (MM) in the Era of New Drugs Phase III study of lenalidomide/bortezomib/dexamethasone.
Early Molecular and Cytogenetic Response Predict for Better Outcomes in Untreated Patients with CML-CP — Comparison of 4 TKI Modalities (Standard- and.
Martinelli G et al. Proc ASH 2015;Abstract 679.
Jabbour E et al. Proc ASH 2015;Abstract 83.
Allogeneic Stem Cell Transplantation (Allo-SCT) for the Treatment of T-Cell Acute Lymphoblastic Leukemia (T-ALL); Evaluation of Minimal Residual Disease.
New Findings in Hematology: Independent Conference Coverage
Ellen K. Ritchie Clinical Director, Richard T. Silver MPN Center
Long-Term Follow-Up of the Imatinib GRAAPH-2003 Study in Newly Diagnosed Patients with De Novo Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia:
Erba HP et al. Blood 2008;112: Abstract 558
R-CHOP Stem Cell Transplantation for Follicular Lymphoma
Anthracycline Dose Intensification in Acute Myeloid Leukemia
First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome–positive (Ph+) acute lymphoblastic.
Assessment of Allogeneic HCT in Older Patients with AML and MDS: A CIBMTR Analysis McClune B et al. ASCO/ASH Symposium 2009;The Best of ASH Special & Plenary.
Final Report Of Single-Center Study Of Chemotherapy Plus Dasatinib For The Initial Treatment Of Patients With Philadelphia-Chromosome Positive Acute Lymphoblastic.
What is the best frontline regimen for CLL patients
Jacob M. Rowe  Biology of Blood and Marrow Transplantation 
Quantifying the Survival Benefit for Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed Acute Myelogenous Leukemia  Paul M. Armistead, Marcos.
Allogeneic Stem Cell Transplantation (Allo-SCT) for the Treatment of T-Cell Acute Lymphoblastic Leukemia (T-ALL); Evaluation of Minimal Residual Disease.
Zaja F et al. Proc ASH 2010;Abstract 966.
Blinatumomab Versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Long-Term Follow-up of Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia:
Anas Younes, M.D. Memorial Sloan Kettering Cancer Center
US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALL by Farhad Ravandi, Megan.
Acute Lymphoblastic Leukemia ⎼ Posters and Abstracts from San Diego
Presentation transcript:

Long-term Outcome after hyper-CVAD and Imatinib for De Novo or Minimally Treated Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph-ALL) Deborah A. Thomas, Susan O’Brien, Stefan Faderl, Farhad Ravandi, William Wierda, Michael Andreeff, Rebecca Garris, Richard Champlin, Jorge Cortes, Hagop Kantarjian The University of Texas M. D. Anderson Cancer Center

Treatment of Adults with Philadelphia positive (Ph)-ALL in Pre-Imatinib Era CR rates similar to Ph negative ALL Outcome with chemotherapy – Short relapse-free survival (RFS) – 3-year survival (OS) rates 10% – 20% – No single regimen superior Allogeneic stem cell transplant (aSCT) – Improved OS rates 27% – 65% (1 st CR)

aSCT in 1st CR for Ph-ALL: Pre-Imatinib Era StudyNo. %OS %TRM aSCTChemo Dombret et al — Laport et al 7954—31 Goldstone et al — Fielding et al*26744 (MRS) 36 (MUD) *Only RFS significant for aSCT after accounting for age, leukocyte count

Imatinib + Hyper-CVAD in Ph-ALL: Rationale Single agent activity of imatinib – CR rate ~20%; marrow CR 10% – 55% – Median time to progression 2 – 4 mos Synergy in vitro with chemotherapy – Cytarabine, anthracyclines, vincristine Hyper-CVAD regimen in de novo Ph-ALL – CR rate 90% – Median CR duration 16 mos – Historical rate aSCT in 1st CR 15% Druker et al, NEJM 345:1038, 2001; Ottmann et al, Blood 100:1965, 2002 Hofmann et al, Leuk Lymph 45:655, 2004; Kantarjian et al, JCO 18:547, 2000

Imatinib + Hyper-CVAD in Ph-ALL Hyper-CVAD MTX-cytarabine Imatinib (400 mg then 600 mg) Vincristine + prednisone Intensive phase Maintenance phase 12 mos Thomas et al, Blood 103:4396, 2004 Imatinib (600 mg then 800 mg)

Imatinib + Hyper-CVAD in Ph-ALL: Eligibility Ph chromosome or BCR-ABL + ALL – De novo untreated – Primary refractory: failure 1 induction – CR after 1 cycle of induction (CR at start) Residual disease by FISH or RT-PCR Imatinib naive Age 15 years or older Adequate hepatorenal function Adequate cardiac function

Imatinib + Hyper-CVAD in Ph-ALL: Induction Response (n=54) Category No. CR/Total %CR De Novo 36/39 92 Primary refractory 6/6 100 CR at start 9 — De novo failures: 1 CRp, 1 PR, 1 early death (sepsis) Molecular CR (nested PCR for BCR-ABL) in 52%

Imatinib + Hyper-CVAD in Ph-ALL Characteristics of de novo groups Parameter Percent Imatinib + HCVAD HCVAD (n=39) (n=50) Age > 60 yrs26 30 WBC > 30 x 10 9 /L Hgb < 10 g/dL Albumin < 3 g/dL Zubrod PS > 2 — 4 LDH > 620 U/L CNS disease 13 2 B2 microglobulin >

Imatinib + Hyper-CVAD in de novo Ph-ALL Parameter Percent Imatinib + HCVAD HCVAD (n=39) (n=50) Response CR Courses to CR > 2 — 11 Median days to CR 21 20

Imatinib + Hyper-CVAD in Ph-ALL: Outcome After CR CR (n=51) Chemo (n=35) [14] SCT (n=16) [2] CCR (n=10) [8] Deaths in CR (n=10) [3] Relapse (n=15) [3] CCR (n=10) [2] Deaths in CR (n=4) [0] Relapse (n=2) [0] 7 infection; 1 pancreatitis, 1 CNS hemorrhage; 1 unknown 2 infection; 2 GVHD [No. with molecular CR]

Thomas et al, ASH 2006

Thomas et al, ASH 2007

Imatinib + Hyper-CVAD in Ph-ALL: Relapses 6 relapses on program – Most between 8 – 21 mos, 1 at 42 mos 5 relapses after change in TKI therapy – Persistent Ph or ↑ BCR-ABL by PCR 2 after aSCT without imatinib maintenance ABL sequencing in 5 of 10 relapses – 5 with ABL KD mutations (none T315I) – Y253H, Y253F, V338G, F359V, E459K Salvageable with hyper-CVAD + dasatinib

Improvements in outcome with continuous imatinib simultaneously with hyper-CVAD Durable remissions – aSCT in 1st CR appears beneficial JALSG ALL202, GRAAPH-2003 Elderly group may benefit from RIC SCT – PCR for BCR-ABL not predictive relapse – ABL KD mutations relatively less common Second or later generation tyrosine kinase inhibitors may further improve outcome Imatinib + Hyper-CVAD in Ph-ALL: Conclusions